Motor Cortex Stimulation for Refractory Facial Neuralgia and Paresthesia in Ramsay Hunt Syndrome.

This study explores motor cortex stimulation (MCS) as a treatment for Ramsay Hunt syndrome (RHS)-related neuralgia, which often persists despite traditional therapies. A 68-year-old patient with RHS experienced significant pain and sensory relief after MCS, after ineffective conventional treatments. MCS enhances neural plasticity, offering a promising alternative for managing intractable neuralgia and sensory disturbances in RHS patients.

Application of multimodal deep learning and multi-instance learning fusion techniques in predicting STN-DBS outcomes for Parkinson's disease patients.

Parkinson's Disease (PD) is a progressive neurodegenerative disorder with substantial impact on patients' quality of life. Subthalamic nucleus deep brain stimulation (STN-DBS) is an effective treatment for advanced PD, but patient responses vary, necessitating predictive models for personalized care. Recent advancements in medical imaging and machine learning offer opportunities to enhance predictive accuracy, particularly through deep learning and multi-instance learning (MIL) techniques.

Percutaneous Balloon Compression Guided by a Compression-Time Effect in Trigeminal Nerve Branches.

Background: Percutaneous balloon compression (PBC) is an important treatment for trigeminal neuralgia (TN). Establishing the duration of balloon compression involves a tradeoff between outcome and postoperative complications. We aimed to explore the effect of the duration of balloon compression on the numbness response in areas innervated by the branches of the trigeminal nerve.

Neuromodulation for postherpetic neuralgia: Preliminary experience in a single center.

Background: Postherpetic neuralgia (PHN) after herpes zoster is a debilitating complication that severely affects the quality of life of patients. Neuromodulation such as spinal cord stimulation (SCS) and trigeminal semilunar ganglion stimulation (TSGS) have become effective methods for treating postherpetic neuralgia.

Methods: A retrospective analysis of clinical data from 30 patients with postherpetic neuralgia who underwent SCS or TSGS treatment from January 2022 to January 2024.

Functional Connectivity and Anxiety Improvement After Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease.

Background: Anxiety is one of the most common and disturbing non-motor symptoms of Parkinson's disease (PD). However, few studies have explored the relationship between functional connectivity (FC) and the rate of anxiety improvement after subthalamic nucleus deep brain stimulation (STN-DBS). Therefore, in this study, we aimed to explore the correlation between FC and the rate of anxiety improvement in patients with PD who underwent STN-DBS.

Relationship between serum uric acid levels and the outcome of STN-DBS in Parkinson's disease.

Background: Uric acid is a natural antioxidant and it has been shown that low levels of uric acid may be a risk factor for the development of Parkinson's disease. We aimed to investigate the relationship between uric acid and improvement of motor symptoms in patients with Parkinson's disease after subthalamic nucleus deep brain stimulation.

Methods: We analyzed the correlation between serum uric acid levels in 64 patients with Parkinson's disease and the rate of improvement of motor symptoms 2 years after subthalamic nucleus deep brain stimulation.

Development and Validation of a Prediction Model for Anxiety Improvement after Deep Brain Stimulation for Parkinson Disease.

Background: Parkinson's disease (PD) represents one of the most frequently seen neurodegenerative disorders, while anxiety accounts for its non-motor symptom (NMS), and it has greatly affected the life quality of PD cases. Bilateral subthalamic nucleus deep brain stimulation (STN-DBS) can effectively treat PD. This study aimed to develop a clinical prediction model for the anxiety improvement rate achieved in PD patients receiving STN-DBS.

Prediction of STN-DBS for Parkinson's disease by uric acid-related brain function connectivity: A machine learning study based on resting state function MRI.

Introduction: Parkinson's disease (PD) is a neurodegenerative disorder characterized by dyskinesia and is closely related to oxidative stress. Uric acid (UA) is a natural antioxidant found in the body. Previous studies have shown that UA has played an important role in the development and development of PD and is an important biomarker.

Nomogram for Predicting Depression Improvement after Deep Brain Stimulation for Parkinson's Disease.

Background: Parkinson's disease is a common neurodegenerative disease, with depression being a common non-motor symptom. Bilateral subthalamic nucleus deep brain stimulation is an effective method for the treatment of Parkinson's disease. Thus, this study aimed to establish a nomogram of the possibility of achieving a better depression improvement rate after subthalamic nucleus deep brain stimulation in patients with Parkinson's disease.

A New Application of Functional Zonal Image Reconstruction in Programming for Parkinson's Disease Treated Using Subthalamic Nucleus-Deep Brain Stimulation.

Objective: Programming plays an important role in the outcome of deep brain stimulation (DBS) for Parkinson's disease (PD). This study introduced a new application for functional zonal image reconstruction in programming.

Methods: Follow-up outcomes were retrospectively compared, including first programming time, number of discomfort episodes during programming, and total number of programming sessions between patients who underwent image-reconstruction-guided programming and those who underwent conventional programming.

Nomogram to Predict Cognitive State Improvement after Deep Brain Stimulation for Parkinson's Disease.

Purpose: Parkinson's disease (PD) is a common neurodegenerative disease, for which cognitive impairment is a non-motor symptom (NMS). Bilateral subthalamic nucleus deep brain stimulation (STN-DBS) is an effective treatment for PD. This study established a nomogram to predict cognitive improvement rate after STN-DBS in PD patients.

Bilateral Globus Pallidus Interna Combined With Subthalamic Nucleus Variable Frequency Deep Brain Stimulation in the Treatment of Young-Onset Parkinson's Disease With Refractory Dyskinesia: A Case Report.

Main motor characteristics in Parkinson's disease (PD) include bradykinesia, rigidity, and tremors. With the development of neuromodulation techniques, it has become possible to use deep brain stimulation (DBS) to control the symptoms of PD. However, since the subthalamic nucleus(STN) and globus pallidus interna (GPi) DBS have their own advantages and disadvantages, it is difficult to control symptoms of the patients.

Application of multimodal MRI and radiologic features for stereotactic brain biopsy: insights from a series of 208 patients.

Objectives: We reviewed our institutional experience during a 10-year period for improvement of safety and efficacy of stereotactic biopsy procedures.

Methods: We performed a retrospective review of inpatient summaries, stereotactic worksheets and radiologic investigations of 208 consecutive patients, who underwent MRI-guided stereotactic biopsies between March 2010 and March 2020.

Results: The overall diagnostic yield was 96.

In vivo detection of metabolic changes in the striatum of proteasomal inhibition-induced Parkinson's disease in rats using proton MR spectroscopy at 9.4 T.

Parkinson's disease is a progressive disorder. To investigate the biochemical alterations in the striatum of rats with different stages of Parkinson's disease induced by proteasomal inhibition, we quantified neurochemical profiles of the striatum using proton magnetic resonance spectroscopyusing 9.4 T ultra-high field imaging.

Retractorless Surgery for Giant Vestibular Schwannomas via the Retrosigmoid Approach.

Background: A fixed retractor is routinely used during surgery for vestibular schwannoma to maintain the surgical corridor; however, brain injuries can be caused by use of retractors. The aim of this study was to present strategies for retractorless surgery for giant vestibular schwannomas and compare retractorless surgery with traditional retractor-assisted surgery to illustrate feasibility and potentially superiority of retractorless surgery.

Methods: Clinical data of 61 patients with giant (≥4 cm diameter) vestibular schwannomas undergoing craniotomy were retrospectively analyzed.

How does conserved dopamine neurotrophic factor protect against and rescue neurodegeneration of PC12 cells?

Conserved dopamine neurotrophic factor protects and rescues dopaminergic neurodegeneration induced by 6-hydroxydopamine , but its potential value in treating Parkinson's disease remains controversial. Here, we used the proteasome inhibitors lactacystin and MG132 to induce neurodegeneration of PC12 cells. Afterwards, conserved dopamine neurotrophic factor was administrated as a therapeutic factor, both pretreatment and posttreatment.

Combined pretreatment with torrefaction and washing using torrefaction liquid products to yield upgraded biomass and pyrolysis products.

This study presented an approach to upgrade biomass and pyrolysis products using a process based on torrefaction liquid washing combined with torrefaction pretreatment. The torrefaction of cotton stalk was first conducted at 250°C for 30min and then the resulting torrefaction liquid products were collected and reused to wash cottonstalk. The pyrolysis of the original and pretreated cotton stalk was performed at 500°C for 15min in a fixed-bed reactor.

Protective and reversal effects of conserved dopamine neurotrophic factor on PC12 cells following 6-hydroxydopamine administration.

Conserved dopamine neurotrophic factor (CDNF), a member of the mammalian mesencephalic astrocyte-derived neurotrophic factor family of conserved secreted factors, has been reported to protect and rescue dopaminergic neurons in vivo. PC12 pheochromocytoma cells are widely used as a cell model for Parkinson's disease (PD) for experimental studies. In the present study, PC12 cells were induced using 6-hydroxydopamine (6-OHDA) to mimic PD, which was used to investigate the protective and reversal effects of CDNF against PD in vitro.

Effects of engineered conserved dopamine neurotrophic factor-expressing bone marrow stromal cells on dopaminergic neurons following 6-OHDA administrations.

Numerous lines of evidence previously indicated that conserved dopamine neurotrophic factor (CDNF) has potential therapeutic value for Parkinson's disease (PD); however, this hypothesis remains controversial. In the present study, the therapeutic effects of engineered CDNF-expressing bone marrow stromal cells (CDNF-BMSCs) on dopaminergic (DA) neurons were evaluated in vivo. CDNF-BMSCs and control BMSCs were transplanted into the rat striatum and one week later, 6-hydroxydopamine (6-OHDA) was administered to induce neurotoxicity.

Comparing neuroprotective effects of CDNF-expressing bone marrow derived mesenchymal stem cells via differing routes of administration utilizing an in vivo model of Parkinson's disease.

The potential value of cerebral dopamine neurotrophic factor (CDNF) in treating Parkinson's disease (PD) remains controversial. To evaluate the therapeutic effects of CDNF-expressing bone marrow derived mesenchymal stem cell (CDNF-MSCs) injections in a rat model of Parkinson's disease, we chose three different routes of CDNF-MSC administration, including intra-striatal, intra-ventricular, and intravenous pathways. Parkinsonism was induced by intra-striatal unilateral injection of 6-OHDA and then rats were subsequently randomized into three groups for either intra-striatal, intra-ventricular or intravenous injection for CDNF-MSC grafting.

Effects of CDNF on 6-OHDA-induced apoptosis in PC12 cells via modulation of Bcl-2/Bax and caspase-3 activation.

Progressive dopamine neuron degeneration in the substantia nigra pars compacta is considered the most prominent pathological characteristic of Parkinson's disease (PD). Currently, there is no cure, but only the capability to relieve the symptoms of PD. The conserved dopamine neurotrophic factor (CDNF) protects and rescues dopamine neurons in vivo.

The analysis of differential induction of hsp70 in the related cerebral domains and nerve fibers of rats after proteasome inhibiton.

Background: Parkinson's disease (PD) is popularly called "proteins conformation disease". Heat shock proteins (Hsps) are essential molecular chaperones that handle abnormal protein conformations. The hsp70 family, in particular, represents the most highly conserved molecular chaperones.

Does neurotrophic factor benefit to PD therapy via co-function with ubiquitin-proteasome system?

Parkinson's disease (PD) is a common progressive neurodegenerative disorder whose core symptoms are tremor, bradykinesia, rigidity, and postural instability. Currently available treatment of PD is mainly based on dopamine replacement strategy to provide relief of motor symptoms, but cannot halt or reverse the degenerative processes of disease. Considerable in vitro and in vivo studies have found that neurotrophic factor (NTF) has neuroprotective or even neurorestorative properties on dopaminergic (DA) system, promoting them become promising candidates for the treatment of PD.